Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

August 30, 2005 09:56 ET

Sutura Launches Pre-TCT Conference Marketing Campaign

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Aug. 30, 2005) - Sutura®, Inc. ("Sutura") (OTCBB:SUTU), a California-based medical device company, announced today that it has launched its new marketing campaign leading up to the 2005 TCT Convention in Washington, DC. The new marketing campaign includes a complete redesign of the Company's website which kicked off the launch earlier this week (www.suturaus.com).

"It is important that as we increase the number of physicians being introduced to our SuperStitch vascular suturing device that we refine our marketing efforts to better showcase the product," said Anthony Nobles, CEO/President of Sutura. "This is particularly true as we close in on the annual TCT Conference in mid-October which is the largest annual gathering of interventional cardiologists, radiologists, vascular medicine specialists, and surgeons."

"The new look marketing campaign also coincides with the expansion of our SuperStitch sales and marketing team in North America," said Tom Lindsey, Director of U.S. Sales & Marketing. "It has been gratifying to see the company attracting top notch, seasoned vascular product sales representatives."

The TCT conference (www.tct2005.com) will be attended by thousands of cardiologists, radiologists, vascular medicine specialists, surgeons and other health care professionals with a special interest in the field of interventional vascular therapy and vascular medicine. Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation™ (CRF), is the world's largest scientific symposium for health care professionals dedicated to interventional vascular therapy.

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The SuperStitch products provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures. The SuperStitch products are designed for ease of use by physicians to provide hemostasis. The F8 & F6 SuperStitch device is designed for use with or without an access device (e.g., trocar sheath, or cannula), for use during minimally invasive surgical procedures, fluoroscopically guided procedures, or in an open setting. Within the United States the F8 & F6 SuperStitch device has been cleared by the FDA under section 510(k) of the Federal Food, Drug, and Cosmetic Act ("FDC Act") for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch F8 & F6 is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    1-866-676-8386
    www.suturaus.com